麻豆传媒

More fatigue, depression, worse reaction time with enzalutamide as compared with abiraterone

Pembrolizumab leads to improved OS; single-agent nivolumab fails to impact DFS

Multiparametric Stockholm3 avoided far more unnecessary biopsies without sacrificing sensitivity

Benefit more than double with the immune checkpoint inhibitor compared with observation

Combination improved PFS versus more hormonal therapy, but control arm questioned

In small first-line trial, PFS more than doubled with combination

OS, PFS, cancer-specific survival all improved, with no increase in toxicity

Updated trial data show nivolumab/cabozantinib doublet "is getting better with age"

KEYNOTE-057 trial results suggest DFS benefit for patient population with unmet need

But add-on abiraterone and apalutamide may offer some benefits in those with higher PSA

Final PROpel analysis also shows trend toward overall survival improvement with PARP inhibitor

Combination achieved a 37% reduction in risk of progression, death versus ARPI alone

Benefit in selected patients seen over physician's choice of docetaxel or second-generation ARPI

Atezolizumab did show some activity, with a 30% overall response rate